{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:24:55Z","timestamp":1773941095418,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172604"],"award-info":[{"award-number":["82172604"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CSCO Clinical Oncology Research Foundation","award":["Y-2022HER2AZMS-0258"],"award-info":[{"award-number":["Y-2022HER2AZMS-0258"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05592-7","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:14:10Z","timestamp":1743743650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Siming","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinchang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huayan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"5592_CR1","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1007\/s00345-020-03576-3","volume":"39","author":"B Alm\u00e5s","year":"2021","unstructured":"Alm\u00e5s B, Halvorsen OJ, Johannesen TB, Beisland C (2021) Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study. World J Urol. 39:3385\u201391. https:\/\/doi.org\/10.1007\/s00345-020-03576-3","journal-title":"World J Urol."},{"key":"5592_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","volume":"62","author":"G Lughezzani","year":"2012","unstructured":"Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M et al (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100\u2013114. https:\/\/doi.org\/10.1016\/j.eururo.2012.02.030","journal-title":"Eur Urol"},{"key":"5592_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cell.2017.09.007","volume":"174","author":"AG Robertson","year":"2018","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD et al (2018) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 174:1033. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007","journal-title":"Cell"},{"key":"5592_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","volume":"72","author":"TJ Moss","year":"2017","unstructured":"Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE et al (2017) Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol 72:641\u2013649. https:\/\/doi.org\/10.1016\/j.eururo.2017.05.048","journal-title":"Eur Urol"},{"key":"5592_CR5","doi-asserted-by":"publisher","first-page":"75.e1-.e8","DOI":"10.1016\/j.urolonc.2020.06.010","volume":"39","author":"X Li","year":"2021","unstructured":"Li X, Li S, Chi Z, Cui C, Si L, Yan X et al (2021) Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. Urol Oncol Semin Original Investig 39:75.e1-.e8. https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.010","journal-title":"Urol Oncol Semin Original Investig"},{"key":"5592_CR6","unstructured":"EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. European Association of Urology 2024."},{"key":"5592_CR7","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","volume":"17","author":"DF Bajorin","year":"1999","unstructured":"Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI et al (1999) Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173\u20133181. https:\/\/doi.org\/10.1200\/JCO.1999.17.10.3173","journal-title":"J Clin Oncol"},{"key":"5592_CR8","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","volume":"28","author":"J Bellmunt","year":"2010","unstructured":"Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E et al (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28:1850\u20131855","journal-title":"J Clin Oncol"},{"key":"5592_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.euo.2020.12.006","volume":"4","author":"AR Khaki","year":"2021","unstructured":"Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D et al (2021) A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors. Eur Urol Oncol 4:464\u2013472. https:\/\/doi.org\/10.1016\/j.euo.2020.12.006","journal-title":"Eur Urol Oncol"},{"key":"5592_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005977","author":"A Bamias","year":"2023","unstructured":"Bamias A, Merseburger A, Loriot Y, James N, Choy E, Castellano D et al (2023) New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2022-005977","journal-title":"J Immunother Cancer"},{"key":"5592_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/jnci\/djt015","volume":"105","author":"AB Apolo","year":"2013","unstructured":"Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE et al (2013) Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst 105:499\u2013503. https:\/\/doi.org\/10.1093\/jnci\/djt015","journal-title":"J Natl Cancer Inst"},{"key":"5592_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.eururo.2012.11.042","volume":"63","author":"G Sonpavde","year":"2013","unstructured":"Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ et al (2013) Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 63:717\u2013723. https:\/\/doi.org\/10.1016\/j.eururo.2012.11.042","journal-title":"Eur Urol"},{"key":"5592_CR13","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1002\/cncr.28146","volume":"119","author":"MD Galsky","year":"2013","unstructured":"Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T et al (2013) Nomogram for predicting survival in patients with unresectable and\/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 119:3012\u20133019. https:\/\/doi.org\/10.1002\/cncr.28146","journal-title":"Cancer"},{"key":"5592_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00897","author":"BA Rader","year":"2017","unstructured":"Rader BA (2017) Alkaline phosphatase, an unconventional immune protein. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.00897","journal-title":"Front Immunol."},{"key":"5592_CR15","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1245\/s10434-013-3349-z","volume":"21","author":"N Tanaka","year":"2014","unstructured":"Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Kobayashi H, Ide H et al (2014) Metastatic behavior of upper tract urothelial carcinoma after radical nephroureterectomy: association with primary tumor location. Ann Surg Oncol 21:1038\u20131045. https:\/\/doi.org\/10.1245\/s10434-013-3349-z","journal-title":"Ann Surg Oncol"},{"key":"5592_CR16","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.eururo.2011.04.029","volume":"60","author":"CT Nguyen","year":"2011","unstructured":"Nguyen CT, Kattan MW (2011) How to tell if a new marker improves prediction. Eur Urol 60:226\u2013228. https:\/\/doi.org\/10.1016\/j.eururo.2011.04.029","journal-title":"Eur Urol"},{"key":"5592_CR17","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM et al (2018) Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol 36:1685\u20131694. https:\/\/doi.org\/10.1200\/JCO.2017.75.7740","journal-title":"J Clin Oncol"},{"key":"5592_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","volume":"126","author":"KS Shohdy","year":"2022","unstructured":"Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R et al (2022) Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br J Cancer 126:430\u2013439. https:\/\/doi.org\/10.1038\/s41416-021-01648-8","journal-title":"Br J Cancer"},{"key":"5592_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.106","author":"TB Powles","year":"2023","unstructured":"Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J et al (2023) LBA6 EV-302\/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC). Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.106","journal-title":"Ann Oncol"},{"key":"5592_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles T, Csoszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng SY et al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 22:931\u2013945. https:\/\/doi.org\/10.1016\/S1470-2045(21)00152-2","journal-title":"Lancet Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05592-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05592-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05592-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:50:51Z","timestamp":1767966651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05592-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5592"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05592-7","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of Peking University Cancer Hospital and Institute approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"206"}}